https://rheumpharm.co.uk/resources/670/2022-09-26T10:54:11+01:00https://rheumpharm.co.uk/resources/bsr-non-biologic-dmard-guidelines/2023-01-20T12:13:51+00:00https://rheumpharm.co.uk/resources/the-british-society-for-rheumatology-biologic-dmard-safety-guidelines-in-inflammatory-arthritis/2023-01-20T12:10:44+00:00https://rheumpharm.co.uk/resources/new-the-2022-british-society-for-rheumatology-guideline-for-the-treatment-of-psoriatic-arthritis-with-biologic-and-targeted-synthetic-dmards/2023-01-20T12:12:28+00:00https://rheumpharm.co.uk/resources/british-society-for-rheumatology-guideline-on-prescribing-drugs-in-pregnancy-and-breastfeeding-comorbidity-medications-used-in-rheumatology-practice-nov-2022british-society-for-rheumatology-guideline/2023-01-20T12:09:22+00:00https://rheumpharm.co.uk/resources/british-society-for-rheumatology-guideline-on-prescribing-drugs-in-pregnancy-and-breastfeeding-immunomodulatory-anti-rheumatic-drugs-and-corticosteroids-nov-2022-2/2023-01-20T12:08:01+00:00https://rheumpharm.co.uk/resources/gmmmg-high-cost-drug-pathway-rheumatoid-arthritis-in-adults/2023-09-08T11:42:06+01:00https://rheumpharm.co.uk/resources/gmmmg-high-cost-drug-pathway-for-psoriatic-arthritis-in-adults/2023-09-08T11:43:21+01:00https://rheumpharm.co.uk/resources/gmmmg-high-cost-drug-pathway-for-ankylosing-spondylitis-in-adults/2023-09-08T11:45:12+01:00https://rheumpharm.co.uk/resources/high-cost-drug-prescribing-and-monitoring-guideline-in-mft-adult-rheumatology/2023-09-08T11:47:02+01:00https://rheumpharm.co.uk/resources/mft-infliximab-guideline-eligibility-approval-pre-treatment-checklists-prescribing-administration-and-monitoring-in-adults/2023-09-08T11:48:42+01:00https://rheumpharm.co.uk/resources/mft-belimumab-intravenous-administration-guideline-in-adults/2023-09-08T11:50:29+01:00https://rheumpharm.co.uk/resources/mft-tocilizumab-guideline-eligibility-approval-pre-treatment-checklists-prescribing-administration-and-monitoring-in-adults/2023-09-08T11:51:50+01:00https://rheumpharm.co.uk/resources/mft-abatacept-guideline-eligibility-approval-pre-treatment-checklists-prescribing-administration-and-monitoring-in-adults/2023-09-08T11:52:49+01:00https://rheumpharm.co.uk/resources/mft-rituximab-guideline-eligibility-approval-pre-treatment-checklists-prescribing-administration-and-monitoring-in-adults/2023-09-08T11:54:00+01:00